RT Journal Article
T1 Current status of terpenoids as inflammasome inhibitors
A1 González Cofrade, Laura
A1 Cuadrado Berrocal, Irene
A1 Heras Polo, Beatriz De Las
A1 Hortelano, Sonsoles
AB Increasing evidence supports NLRP3 inflammasome as a new target to control inflammation. Dysregulation of NLRP3 inflammasome has been reported to be involved in the pathogenesis of several human inflammatory diseases. However, no NLRP3 inflammasome inhibitors are available in clinic. Terpenoids are natural products with multi-target activities against inflammation. Recent studies have revealed that these compounds are capable of inhibiting the activation of NLRP3 inflammasome in several mouse models of NLRP3 inflammasomerelated pathogenesis. Thus, terpenoids represent an interesting pharmacological approach for the treatment of inflammatory diseases as they are endowed with a dual mechanism of inhibition of NF-KB transcription factor and inflammasome activation, both critically involved in their anti-inflammatory effects. This work provides an overview of the current knowledge on the therapeutic potential of terpenoids as NLRP3 inflammasome inhibitors.
PB Elsevier
YR 2019
FD 2019-11-28
LK https://hdl.handle.net/20.500.14352/118892
UL https://hdl.handle.net/20.500.14352/118892
LA eng
NO Hortelano S, González-Cofrade L, Cuadrado I, De Las Heras B. Current status of terpenoids as inflammasome inhibitors. Biochemical Pharmacology 2020;172:113739. https://doi.org/10.1016/j.bcp.2019.113739.
NO FIS
NO ISCIII and Spanish Ministry of Health (Instituto de Salud Carlos III)
NO Ministerio de Economia y Competitividad
DS Docta Complutense
RD 10 abr 2025